LINEAGE CELL THERAPEUTICS IN (LCTX) Stock Income Statement
NYSEARCA:LCTX - NYSE Arca - US53566P1093 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 9.50M | 8.95M | 14.70M | 4.34M | 1.83M | |||
| Minority Interest Expense | -27.00K | -7.00K | 80.00K | 250.00K | 40.00K | |||
| Cost Of Goods | 334.00K | 671.00K | 730.00K | 1.43M | 390.00K | |||
| Gross Profit | 9.16M | 8.27M | 13.98M | 2.92M | 1.44M | |||
| Operating Expenses | 30.64M | 33.01M | 36.49M | 52.12M | 27.88M | |||
| Research and Development | 12.45M | 15.61M | 13.89M | 33.71M | 11.12M | |||
| Selling, General, and Administrative Expenses | 18.17M | 17.30M | 22.51M | 18.21M | 15.57M | |||
| Operating Income | -21.48M | -24.73M | -22.52M | -49.21M | -26.45M | |||
| Interest Income/Expense | 1.45M | 1.63M | -1.37M | 3.73M | 1.82M | |||
| Other Income/Expense | 1.45M | -178.00K | -1.93M | 1.69M | 2.71M | |||
| Non Recurring Items | N/A | N/A | 0.00 | 520.00K | N/A | |||
| Income Before Taxes | -18.58M | -23.28M | -25.81M | -43.27M | -21.92M | |||
| Income Tax | 0.00 | -1.80M | 540.00K | 0.00 | -1.24M | |||
| Net Income | -18.61M | -21.49M | -26.27M | -43.02M | -20.65M | |||
| EBITDA | -20.87M | -24.04M | -21.79M | -48.34M | -24.33M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.09 | -0.12 | -0.15 | -0.26 | -0.14 | |||
| Non GAAP EPS | -0.10 | -0.13 | -0.15 | -0.26 | -0.14 | |||
| Statistics | ||||||||
| Gross Profit Margin | 96.48% | 92.50% | 95.10% | 67.28% | 78.69% | |||
| Profit Margin | -195.90% | -240.20% | -178.71% | -991.24% | -1128.42% | |||
| Operating Profit Margin | -226.11% | -276.50% | -153.20% | -1133.87% | -1445.36% | |||
All data in USD